PepTalk 2017
PepTalk 2017
Archived Content

Pipeline 3 Header 

Second Annual
Bispecific Antibody Therapeutics
Engineering Multi-Specificity
January 24-25, 2013 


Day 1 | Day 2 | Download Pipeline 3 Brochure 

Creating bioactive molecules that are multivalent and multifunctional offers the promise of more effective therapeutics. By binding to at least two molecular targets simultaneously, Antibodies are empowered, thereby delivering a highly potent therapeutic, particularly for cancer immunotherapy.This meeting will explore the challenges of engineering multi-specificity to ensure stability and efficacy, and will review the numerous forms of multi-specific antibodies. Safety issues will be given particular focus, as will PK and immunogenicity. Case studies will be presented that highlight pre-clinical development as well as clinical data. Join colleagues from around the world in this discussion of the exciting breakthroughs in engineering antibodies, and see how cancer and other applications are advancing into a true therapeutic revolution.


1:00-2:00 pm Conference Registration


Reaching for Success 

1:45  Chairperson’s Opening Remarks

David E. Szymkowski, Ph.D., Senior Director, Biotherapeutics, Xencor, Inc.

» Opening Keynote Presentation: 

1:50  Clinical Activity of BiTE Antibody Blinatumomab in B-Cell  Malignancies

Max ToppMax Topp, M.D., Professor, Internal Medicine II, University of Würzburg

» Featured Presentation: 

2:35  Advances in Next Generation Bispecific Antibodies: Opportunities in Improving on Safety, PK-PD, CMC and Efficacy

Rakesh DixitRakesh Dixit, Ph.D., DABT, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune - Biography 

It is becoming increasingly apparent that bispecific antibodies can not only modulate two targets simultaneously, but they have additional potential to redirect immune system effector cells, such as cytotoxic T cells or natural killer cells, and take advantage of cytotoxic payloads. I will focus on the following key topics: innovation in bispecific formats; utility and limitations; opportunities of demonstration of superiority of bispecific biologics over combination biologics; Safety, PK-PD, CMC issues; and clinical efficacy.

3:05  Delivery of Therapeutic Antibodies Across the Blood-Brain Barrier

James A. ErnstJames A. Ernst, Scientist, Protein Chemistry, Genentech, Inc. - Biography 

This presentation will demonstrate the identification of an antibody targeting the Transferrin Receptor to facilitate transport across the Blood-Brain Barrier (BBB). When combined with a high affinity antibody inhibiting -secretase (BACE1), a protease essential to processing amyloid precursor protein a bispecific antibody is created which shows improved ability to inhibit production of the amyloid- in the brain providing a potentially novel approach to the treatment of Alzheimer’s disease.

3:35  Sponsored Presentation (Opportunity Available)

3:50  Refreshment Break in the Exhibit Hall with Poster Viewing


Targeting Cancer 

» Featured Presentation: 

4:30  Vaccination with Targeted T Cells for Solid Tumors and Hematologic Malignancies

Lawrence LumLawrence Lum, M.D., D.Sc., Professor, Oncology, Karmanos Cancer Institute - Biography 

Heteroconjugated bispecific antibodies directed at Her2/neu and CD20 can be used to target solids tumors and hematologic malignancies.  Strategies will be discussed that were used to show that infusions of bispecific antibody armed activated T cells can induce anti-tumor immunity that can be transferred with autologous stem cell transplantation in the marrow inoculum or in immune activated T cells.

5:00  Bispecific IgG-Based Therapy of Hematological and Solid Tumors

Mark ThrosbyMark Throsby, Ph.D., COO, Research and Development, Merus BV - Biography 

Merus is developing a distinctive multispecific antibody therapeutics pipeline for treatment of cancer patients. The pipeline includes bispecific antibodies that allow the simultaneous targeting of different growth factor receptors involved in tumorigenesis. In another application, bispecific antibodies are used to redirect T cells to tumor cells for efficient tumor cell killing. Both approaches benefit from bispecific human antibodies with a natural IgG format in terms of manufacturing and application in humans.

5:30  A Stable IgG-Like Bispecific Antibody Targeting the Epidermal Growth Factor Receptor and the Type I Insulin-Like Growth Factor Receptor Demonstrates Superior Anti-Tumor Activity

William Snyder, Ph.D., Associate Research Scientist, Pfizer Centers for Therapeutic Innovation

EGFR and IGF-1R cooperate to promote tumor progression and drug resistance. Here, the characterization of a stable IgG-like bispecific antibody (EI-04) dual-targeting EGFR and IGF-1R will be presented. EI-04 displays favorable biophysical properties for biopharmaceutical development and high in vitro potency for EGFR and IGF-1R binding and inhibition. EI-04 demonstrates enhanced in vivo anti-tumor efficacy over its parental mAbs. Our data support the clinical investigation of EI-04 as a superior cancer therapeutic in treating EGFR and IGF-1R pathway responsive tumors.

6:00  End of Day


Day 1 | Day 2 | Download Pipeline 3 Brochure